Compare TFIN & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TFIN | TNDM |
|---|---|---|
| Founded | 1981 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | N/A | 2013 |
| Metric | TFIN | TNDM |
|---|---|---|
| Price | $59.16 | $21.22 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 19 |
| Target Price | ★ $63.00 | $27.05 |
| AVG Volume (30 Days) | 216.5K | ★ 2.4M |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,014,736,000.00 |
| Revenue This Year | $7.27 | $10.96 |
| Revenue Next Year | $11.31 | $9.33 |
| P/E Ratio | $66.31 | ★ N/A |
| Revenue Growth | N/A | ★ 7.93 |
| 52 Week Low | $42.90 | $10.00 |
| 52 Week High | $77.84 | $29.65 |
| Indicator | TFIN | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 44.12 | 45.19 |
| Support Level | $57.66 | $19.04 |
| Resistance Level | $61.92 | $22.98 |
| Average True Range (ATR) | 2.99 | 1.78 |
| MACD | 0.02 | -0.18 |
| Stochastic Oscillator | 55.45 | 29.36 |
Triumph Financial Inc is a financial holding company. The company has four reportable segments namely Banking, Factoring, Payments, and Intelligence. The Banking segment includes the operations of TBK Bank. The Factoring segment includes the operations of Triumph Financial Services with revenue derived from factoring services, The Payments segment includes the operations of TBK Bank's TriumphPay division which provides a presentment, audit and payment solution to Shipper, Broker, and Factor clients in the trucking industry and The Intelligence segment includes to turn the over-the-road trucking data collected through the services into actionable insights for their customers.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.